Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

The CDMO market was valued at USD 246.11 Billion in 2025. It is poised to grow at a CAGR of 9.10% during the forecast period of 2026-2035, and reach USD 588.00 Billion by 2035. The market growth is driven by the rising pharmaceutical outsourcing to reduce costs, accelerate development timelines, and access advanced manufacturing capabilities, significantly driving market growth.

Key Market Trends and Insights

In April 2026, Recipharm expanded its biologics manufacturing capabilities in Europe to support increasing demand for advanced pharmaceutical outsourcing and compliance with evolving global regulatory standards.

In March 2026, Fujifilm Diosynth Biotechnologies advanced operations at its Holly Springs facility, boosting large-scale biologics production capacity and supporting growing global demand for CDMO services

In February 2026, ESTEVE continued strengthening its CDMO business through strategic investments in small-molecule API manufacturing and expanded operations across North America and Europe.

Market Size and Forecast

  • Market Size (2025): USD 246.11 Billion
  • Projected Market Size (2035): USD 588.00 Billion
  • CAGR (2026-2035): 9.10%

CDMO vs CMO vs CRO: What's the Difference and Why It Matters

The pharmaceutical industry runs on acronyms that often get used interchangeably, but CDMO, CMO, and CRO are three very different types of organizations. Mixing them up can lead to misaligned partnerships, cost overruns, and serious project delays. Here is a straightforward breakdown of what each one actually does.

A CMO (Contract Manufacturing Organization) focuses purely on manufacturing. A pharma company hands over a drug formulation that has already been developed, and the CMO produces it at scale, whether that is API synthesis, tablet compression, fill-finish, or packaging. The CMO's job starts and ends at the production floor. Companies typically turn to CMOs when they need production capacity without the capital investment of building their own facility.

A CRO (Contract Research Organization) sits at the other end of the drug development pipeline. CROs handle the research and clinical side, including preclinical studies, toxicology testing, regulatory submissions, clinical trial management, and bioanalytical work. They function essentially as an outsourced R&D department. A small biotech with a promising molecule but no internal research infrastructure will often partner with a CRO to move from discovery all the way to IND filing.

A CDMO (Contract Development and Manufacturing Organization) does both. It bridges the gap between a CRO's research capabilities and a CMO's production capacity. A pharma or biotech company can bring a molecule to a CDMO at the early development stage and work with that same partner through to commercial launch. This integrated model is what makes CDMOs increasingly attractive to drug developers. Fewer handoffs, fewer tech transfer risks, and one point of accountability throughout the entire process.

In practical terms, the choice between these three depends on where a drug program currently sits. Early-stage research needs point toward a CRO. A product that is already formulated and approved but just needs volume production is a conversation for a CMO. Anything in between, or a company that wants a single partner to handle the full journey, is where CDMOs come in.

One thing worth keeping in mind is that the lines between these categories have blurred over the past few years. Several large CMOs have added development services to compete with CDMOs, and some CROs have built out limited manufacturing capabilities. But at their core, the distinction still holds. Research is CRO territory, manufacturing is CMO territory, and the full development-to-production continuum is where CDMOs operate.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Compound Annual Growth Rate

9.1%

Value in USD Billion

2026-2035


*this image is indicative*

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

CDMO Market Overview

The market is expanding steadily, driven by increasing outsourcing by pharmaceutical and biotechnology companies to reduce costs and accelerate drug development timelines. Rising demand for biologics, complex drug formulations, and personalized medicines is fueling growth. Additionally, technological advancements, regulatory expertise, and capacity expansion by CDMOs are strengthening their strategic importance across global pharmaceutical supply chains. The market reached a value of approximately USD 246.11 Billion in 2025.

CDMO Market Growth Drivers

Strategic Acquisitions to Propel the Market Expansion

Growing demand for specialized drug manufacturing and expanding global pharmaceutical outsourcing are key market drivers. For instance, in July 2025, ESTEVE acquired Regis Technologies to enhance its small-molecule API capabilities and expand its North American presence. This acquisition is anticipated to accelerate API development, strengthen regional supply chains, and boost CDMO competitiveness, supporting long-term market expansion during the forecast period.

CDMO Market Trends

Key trends shaping the market include increasing outsourcing, biologics demand, advanced manufacturing technologies, regulatory compliance focus, and strategic partnerships driving global expansion.

Increasing Regulatory Compliance and Facility Expansion Shaping the Market Landscape

Rising regulatory compliance requirements and increasing demand for high-quality production standards are shaping the market. For instance, in January 2026, Recipharm announced plans to develop a new manufacturing facility aligned with updated FDA requirements, enhancing its compliance capabilities. This development is expected to strengthen GMP facility infrastructure, improve regulatory adherence, and support efficient production scale-up, thereby driving sustained market growth in the forecast period.

CDMO Market Segmentation

Market Breakup by Service Type

  • Contract Manufacturing Organization
    • Active Pharmaceutical Ingredient (API) Manufacturing
      • Small Molecule
      • Large Molecule
      • High Potency (HPAPI)
    • Finished Formulation (FDF) Development and Manufacturing
      • Solid Dose Formulation
      • Liquid Dose Formulation
      • Injectable Dose Formulation
      • Secondary Packaging Services
      • Others
  • Contract Research Organization
    • Pre-Clinical
    • Phase I
    • Phase II
    • Phase III
    • Phase IV

Market Breakup by Therapeutic Area

  • Oncological Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Others

Market Breakup by End User

  • Pharmaceutical and Biopharmaceutical Companies
  • Medical Devices Companies
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Contract Development and Manufacturing Organization (CDMO) Market By Service

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

CDMO Market Share

Oncological Diseases Anticipated to Lead the Market Segment by Therapeutic Area

By therapeutic area, oncological diseases captured more than 34% share of the market size during the historical period, driven by rising global cancer incidence and increasing investment in targeted therapies. The complexity of oncology drug production has encouraged greater reliance on biologics CDMO services. Additionally, expanding pipelines of advanced therapies and personalized medicines continue to reinforce the segment’s dominant position within the market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

CDMO Market Analysis by Region

The Asia Pacific held the largest revenue share of over 37% in the historical period, supported by cost advantages, skilled workforce availability, and expanding pharmaceutical manufacturing infrastructure. Countries such as China and India have emerged as key hubs for outsourcing pharma activities. Favorable regulatory reforms and increasing foreign investments further strengthen regional capabilities, enabling companies to scale production efficiently and meet growing global demand.

Leading Players in the CDMO Market

The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Vetter Pharma-Fertigung GmbH & Co. KG

Vetter Pharma-Fertigung GmbH & Co. KG, founded in 1950 and headquartered in Ravensburg, Germany, is a leading CDMO specializing in aseptic fill and finish services. The company’s portfolio includes prefilled syringes, cartridges, and vials, serving global biopharmaceutical clients. Its expertise in fill-finish manufacturing supports complex injectable drug production and commercialization.

Recipharm AB

Recipharm AB, established in 1995 and headquartered in Stockholm, Sweden, is a global CDMO offering comprehensive pharmaceutical development and manufacturing services. Its portfolio spans drug substance and drug product manufacturing, including oral solids and sterile injectables. The company emphasizes clinical manufacturing capabilities to support early-stage development through commercial supply across international markets.

Boehringer Ingelheim

Boehringer Ingelheim, founded in 1885 and headquartered in Ingelheim, Germany, is a leading pharmaceutical company with a strong CDMO division. Its portfolio includes biologics development, manufacturing, and fill-finish services. The company leverages advanced technologies and bioreactor capacity to support large-scale production of complex biologics for global pharmaceutical partners.

Patheon Pharma Services (Thermo Fisher Scientific Inc.)

Patheon Pharma Services, part of Thermo Fisher Scientific Inc., was established in 1974 and is headquartered in Durham, North Carolina, United States. It provides integrated CDMO solutions, including drug development, manufacturing, and packaging. The company’s portfolio highlights expertise in API development, supporting both small and large molecule production for pharmaceutical clients globally.

Other key players in the market are Pfizer Inc., Famar SA, Lonza Group, LTS Lohmann Therapie-Systeme AG, Aenova Holding GmBH, Fareva SA, FUJIFILM Diosynth Biotechnologies, eXmoor Pharma, B. Braun SE, and Sanofi.

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Key Questions Answered in the CDMO Market

  • What was the CDMO market value in 2025?
  • What is the CDMO market forecast outlook for 2026-2035?
  • What major factors aid the demand for CDMO market?
  • How has the market performed so far, and how is it anticipated to perform in the coming years?
  • What are the market’s major drivers, opportunities, and restraints?
  • What are the major CDMO market trends?
  • Which service type is expected to dominate the market segment?
  • Which therapeutic area is expected to dominate the market segment?
  • Which end user is expected to dominate the market segment?
  • Who are the key players in the CDMO market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

More Insights On

Europe CDMO Market

India CDMO Market

Middle East and Africa CDMO Market

United States CDMO Market

Asia Pacific CDMO Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2025
Historical Period 2019-2025
Forecast Period 2026-2035
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Service Type
  • Therapeutic Area
  • End User
  • Region
Breakup by Service Type
  • Contract Manufacturing Organization
  • Contract Research Organization
Breakup by Therapeutic Area
  • Oncological Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Others
Breakup by End User
  • Pharmaceutical and Biopharmaceutical Companies
  • Medical Devices Companies
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • Recipharm AB
  • Boehringer Ingelheim
  • Patheon Pharma Services (Thermo Fisher Scientific Inc.)
  • Pfizer Inc.
  • Famar SA
  • Lonza Group
  • LTS Lohmann Therapie-Systeme AG
  • Aenova Holding GmBH
  • Fareva SA
  • FUJIFILM Diosynth Biotechnologies
  • eXmoor Pharma
  • B. Braun SE
  • Sanofi

Datasheet

10 % Off

USD

3,299

2,969

Single User License

10 % Off

USD

5,499

4,949

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 5,499

USD 4,949

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us